Send a textWe explore the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe.Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access.Here we bring together specialists from our global market access (Rob Taaffe), systematic review (Regina Leadley), and health economic (Calum Jones) teams to explore this environment and some of the key hurdles that Pharmaceutical and Medtech innovators need to overcome in order to achieve patient access.Rob, Regina and Calum discuss:Current and future market events and trends for rare disease products across EuropeClinical evidence development, including tactical challenges around evidence generation and how to address theseBuilding the health economic case, including key principles and tactical nuances for health economic modelling in rare and orphan diseaseThis podcast was originally broadcast as a live webinar on 17th November 2021. To learn more and request a copy of the slides used please visit our website. Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related